BioMarin Pharmaceutical, Inc.
BioMarin is a global biotechnology company founded in 1997, dedicated to translating genetic discoveries into new medicines that improve human health. With a focus on genetic conditions, the company has developed eight approved medicines for conditions such as achondroplasia, severe hemophilia A, and various rare inherited and lysosomal storage diseases. BioMarin's approach involves cutting-edge science rooted in genetic insights, leading to a diverse pipeline of clinical and preclinical candidates. The company operates in over 70 countries, employs around 3,000 people, and is committed to bold science, patient-centric solutions, and community support.
Industries
Nr. of Employees
Very Large (1000+)
BioMarin Pharmaceutical, Inc.
Products
Approved therapeutics for genetically defined rare diseases
A portfolio of marketed medicines for conditions including skeletal dysplasia, severe hemophilia A and several rare inherited and lysosomal storage diseases.
Approved therapeutics for genetically defined rare diseases
A portfolio of marketed medicines for conditions including skeletal dysplasia, severe hemophilia A and several rare inherited and lysosomal storage diseases.
Services
External scientific support
Support for independent medical education, external research collaborations and publication data requests for the scientific community.
Patient support and expanded access programs
Programs to support patients in accessing therapies and resources, including expanded access pathways for eligible individuals.
External scientific support
Support for independent medical education, external research collaborations and publication data requests for the scientific community.
Patient support and expanded access programs
Programs to support patients in accessing therapies and resources, including expanded access pathways for eligible individuals.
Expertise Areas
- Genetic medicine
- Gene therapy development
- Biologics development and enzyme-replacement therapies
- Translational research and biomarker discovery
Key Technologies
- Gene therapy platforms
- Enzyme replacement therapy approaches
- Biologics process development
- Analytical chemistry methods for biologics